Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • Bitcoin USD

    63,559.51
    -472.53 (-0.74%)
     
  • CMC Crypto 200

    1,324.55
    -71.99 (-5.16%)
     
  • S&P 500

    5,102.80
    +54.38 (+1.08%)
     
  • Dow

    38,249.92
    +164.12 (+0.43%)
     
  • Nasdaq

    15,930.53
    +318.77 (+2.04%)
     
  • Gold

    2,348.60
    +6.10 (+0.26%)
     
  • Crude Oil

    84.09
    +0.52 (+0.62%)
     
  • 10-Yr Bond

    4.6730
    -0.0330 (-0.70%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

2 Things About AbbVie That Investors Are Ignoring

2 Things About AbbVie That Investors Are Ignoring

Investors were ready for declines in AbbVie's (NYSE: ABBV) blockbuster immunology drug Humira. The product now is facing competition in the U.S. So, seeing a 26% drop in Humira's U.S. first-quarter sales wasn't a surprise.